ID29778A - Pengobatan kombinasi dari penghambat enzim pengubah angiotensi dan antagonis aldosteron untuk menurunkan morbiditas dan mortalitas dari penyakit kardiovaskuler - Google Patents

Pengobatan kombinasi dari penghambat enzim pengubah angiotensi dan antagonis aldosteron untuk menurunkan morbiditas dan mortalitas dari penyakit kardiovaskuler

Info

Publication number
ID29778A
ID29778A IDW00200100977A ID20010977A ID29778A ID 29778 A ID29778 A ID 29778A ID W00200100977 A IDW00200100977 A ID W00200100977A ID 20010977 A ID20010977 A ID 20010977A ID 29778 A ID29778 A ID 29778A
Authority
ID
Indonesia
Prior art keywords
angiotens
mortality
changes
cardiovascular disease
combination treatment
Prior art date
Application number
IDW00200100977A
Other languages
English (en)
Indonesian (id)
Inventor
Alfonso T Perez
Richard J Lachapelle
Barbara Roniker
Debra J Asner
John C Alexander
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ID29778A publication Critical patent/ID29778A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IDW00200100977A 1998-11-06 1999-11-05 Pengobatan kombinasi dari penghambat enzim pengubah angiotensi dan antagonis aldosteron untuk menurunkan morbiditas dan mortalitas dari penyakit kardiovaskuler ID29778A (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10739898P 1998-11-06 1998-11-06
US12297799P 1999-03-05 1999-03-05
US12297899P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
ID29778A true ID29778A (id) 2001-10-11

Family

ID=27380294

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200100977A ID29778A (id) 1998-11-06 1999-11-05 Pengobatan kombinasi dari penghambat enzim pengubah angiotensi dan antagonis aldosteron untuk menurunkan morbiditas dan mortalitas dari penyakit kardiovaskuler

Country Status (17)

Country Link
US (3) US6410524B1 (zh)
EP (1) EP1126880A2 (zh)
JP (1) JP2002529405A (zh)
KR (1) KR20010100986A (zh)
CN (1) CN1330556A (zh)
AU (1) AU1714000A (zh)
BR (1) BR9915134A (zh)
CA (1) CA2348885A1 (zh)
CZ (1) CZ20011590A3 (zh)
EA (1) EA003782B1 (zh)
HK (1) HK1040056A1 (zh)
HU (1) HUP0104249A3 (zh)
ID (1) ID29778A (zh)
IL (1) IL142911A0 (zh)
NO (1) NO20012229L (zh)
PL (1) PL348198A1 (zh)
WO (1) WO2000027380A2 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250748A1 (en) * 1999-03-05 2005-11-10 G. D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and eplerenone for treatment of cardiovascular disease
US20010039262A1 (en) * 2000-04-26 2001-11-08 Balaji Venkataraman Methods and compositions for the treatment of cardiac indications
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
JP2004505061A (ja) * 2000-07-27 2004-02-19 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とカルシウムチャンネル遮断薬の併用療法
EP1303308B1 (en) * 2000-07-27 2006-09-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
US7534768B2 (en) * 2000-12-13 2009-05-19 Henderson Morely Research And Development Ltd. Treatment of DNA viral infections
US20030225123A1 (en) * 2001-03-22 2003-12-04 Auerbach Bruce Jeffrey Antihypertensive agents and use
US20040156903A1 (en) * 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
ATE357933T1 (de) * 2002-01-15 2007-04-15 Actavis Group Hf Formulierungen von quinapril und verwandte ace- hemmer
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
JP2007534363A (ja) * 2003-12-18 2007-11-29 インバーネス メディカル スウィッツァーランド ゲーエムベーハー モニタリング方法およびモニタリング装置
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
EP1732523B9 (en) 2004-03-30 2010-06-02 Relypsa, Inc. Potassium binding polymers and uses thereof
GB2413282B (en) * 2004-04-23 2009-01-14 Henderson Morley Plc DNA Viral Infections
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20060135497A1 (en) * 2004-12-17 2006-06-22 Ajay Gupta Combination therapy for treating heart disease
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US9884024B2 (en) * 2005-12-27 2018-02-06 Hemant N Joshi Physically dispersed, molecularly dissolved and/or chemically bound drug(s) in an empty, hard capsule shell composition
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
US20090076119A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ramipril
KR20100135909A (ko) 2008-04-17 2010-12-27 사노피-아벤티스 심혈관성 입원 또는 사망을 예방하는데 사용하기 위한 약제의 제조에 있어서의 드로네다론의 용도
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
GB0819635D0 (en) * 2008-10-27 2008-12-03 Auron Invest Ltd A composition for the treatment of hypertension
CN102421433B (zh) * 2009-03-26 2015-09-23 阿贾伊·古普塔 用于治疗肾病的组合物和方法
US20110054033A1 (en) * 2009-08-26 2011-03-03 Virginia Tech Intellectual Properties, Inc. Methods of using abscisic acid for ameliorating hypertension and vascular inflammation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
KR20210005314A (ko) 2012-10-08 2021-01-13 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257390A (en) 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
DE3506100A1 (de) 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NZ510572A (en) * 1995-02-10 2002-11-26 G Use of a combination of angiotensin converting enzyme inhibitor, aldosterone antagonist and diuretic for treating cardiovascular diseases
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
WO1996024373A2 (en) 1995-02-10 1996-08-15 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
AU5982296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist

Also Published As

Publication number Publication date
PL348198A1 (en) 2002-05-06
HK1040056A1 (zh) 2002-05-24
US20040167108A1 (en) 2004-08-26
HUP0104249A3 (en) 2002-06-28
CN1330556A (zh) 2002-01-09
EA200100418A1 (ru) 2001-12-24
NO20012229D0 (no) 2001-05-04
BR9915134A (pt) 2001-08-07
NO20012229L (no) 2001-07-03
AU1714000A (en) 2000-05-29
US6747020B2 (en) 2004-06-08
EA003782B1 (ru) 2003-08-28
US6410524B1 (en) 2002-06-25
CA2348885A1 (en) 2000-05-18
IL142911A0 (en) 2002-04-21
WO2000027380A2 (en) 2000-05-18
EP1126880A2 (en) 2001-08-29
CZ20011590A3 (cs) 2003-01-15
US20030040484A1 (en) 2003-02-27
HUP0104249A2 (hu) 2002-04-29
WO2000027380A3 (en) 2000-08-24
KR20010100986A (ko) 2001-11-14
JP2002529405A (ja) 2002-09-10

Similar Documents

Publication Publication Date Title
ID29778A (id) Pengobatan kombinasi dari penghambat enzim pengubah angiotensi dan antagonis aldosteron untuk menurunkan morbiditas dan mortalitas dari penyakit kardiovaskuler
ID22711A (id) Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa
ID26022A (id) Bentuk galenic pelepasan yang telah diperpanjang dan pelepasan lanjutan yang terdiri dari bahan peningkat absorpsi yang dapat diberikan melalui mulut dan penggunaan bahan peningkat absorpsi tersebut
ID26099A (id) Turunan amida dan antagonis nosiseptin
ID26390A (id) Komposisi untuk pengobatan pernapasan dan penyakit kulit sekurangnya terdiri dari satu leukotrien antagonis dan satu antihistamin
ID22216A (id) Penggunaan antagonis-antagonis reseptor kanabinoid pusat untuk mengatur selera makan
ID19253A (id) Bahan antagonis reseptor vitronektin, pembuatannya dan penggunaannya
ID24481A (id) Gastrokinetik monosiklik benzamida dari derivat-3-atau-tersubstitusi 4-(aminometil)-piperidin
ID24202A (id) Multi-fase agregat yang terdiri dari karbon dan preparasinya
NO995802D0 (no) Anvendelse av oljemasser
DE60043715D1 (de) Brennkraftmaschine und Generatorkombination
ID26945A (id) Komposisi farmasi yang mengandung misel yang terdiri dari glukokortikosteroid lipofilik dan hanya satu surfaktan
FR2807425B1 (fr) Ceramique dielectrique non reductrice et condensateur en ceramique monolitique l'utilisant
DE60035581D1 (de) Salz von amlodipin und atorvastatin
ID27544A (id) Agonis dan antagonis muskarinat
ID22916A (id) Turunan-turunan ergolin dan penggunaannya sebagai antagonis reseptor somatostatin
ID24828A (id) Komposisi-komposisi farmasi dari tizoksianida dan nitazoksanida
IL153937A0 (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
ID19245A (id) Antagonis reseptor vitronektin, pembuatannya dan pemakaiannya
PT1036072E (pt) Antagonistas de receptores de trombina
ATE231681T1 (de) Anwendung von dihydroxychinolinverbindungen zur verlängerung der haltbarkeit von säugetier- und fischprodukten
DZ3361A1 (fr) Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda
DE60011650D1 (de) Synergistische kombination von nk1-rezeptor antagonisten und gaba analogen
ID23222A (id) Mesin yang disempurnakan untuk mencuci dan/atau mengeringkan pakaian
ID30484A (id) Turunan 4-heterosikliksulfonamidil 6 metoksi 5 (2 metoksi fenoksi) 2 piridil-pirimidin, pembuatannya dan penggunaan sebagai antagonis reseptor endotelin